Pando Bioscience (YC W23)

Pando Bioscience is an AI-driven synthetic biology company focused on revolutionizing enzyme engineering for the pharmaceutical manufacturing and diagnostics industries. Their proprietary ultra-high-throughput screening platform allows them to screen 1000-fold more enzymes, 75% faster and 80% cheaper than traditional methods. This empowers their AI models to efficiently optimize enzymes for multiple properties, delivering high-performing, industrial-grade enzymes. Pando offers both proprietary engineered enzymes for molecular biology applications, such as their PD-Phi29 DNA polymerase variant, and custom enzyme solutions tailored to client needs, aiming to reduce costs, improve efficiency, and maximize profitability. They have demonstrated significant value for clients, including a 50% cost reduction and $24M in new profit for a pharma manufacturing customer, and a 120% revenue increase and $45M in new revenue for a diagnostics industry customer.